

Invega Sustenna® Review

1. You are preparing to administer Invega Sustenna® to a patient who weighs 146 pounds. What size needle will you use?

1 1/2 in 22g *1 1/2 in 22g*

2. Name the most common side effects a patient may experience when taking Invega Sustenna®.

jittery, eye shifting, protrusion of tongue, Cerebrovascular adverse reaction (stroke), Neuroleptic malignant syndrome, QT prolongation, tardive dyskinesia, metabolic changes, orthostatic hypotension, Leukopenia, Neutropenia, and Agranulocytosis, hyperprolactinemia, motor and cognitive impairment, seizures

3. What black box warning is associated with this medication?

Increased mortality in elderly pts w/ dementia related psychosis

4. What are the standard recommended Day 1 and Day 8 initiation dosages for a person with schizophrenia?

Day 1 = 234mg *Day 8 = 156mg*

5. What is the standard recommended maintenance dosage for a patient with schizophrenia?

117mg

6. What is the correct location for administration of the Day 1 and Day 8 initiation doses?

Deltoid

7. What are the recommended Day 1 and Day 8 initiation dosages for a person with a creatinine clearance of 65mL/min?

Day 1 = 156mg *Day 8 = 117mg*

8. What would the *recommended* maintenance dosage be for a patient with mild renal impairment?

78mg

9. What is the rationale for a trial of oral paliperidone or oral or injectable risperidone before placing a patient on Invega Sustenna®?

To sure the pt will tolerate it well

10. Name three practices when preparing an intramuscular injection that ensure aseptic technique is maintained throughout the procedure.

Wearing gloves, hand hygiene, making sure to clean area, dont let
needle touch anything

11. Explain the rationale for obtaining consent for this psychoactive medication prior to preparing the medication for administration.

Making sure the patient knows all the important information prior
+ getting it

Autonomy :- right + refuse